Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.34 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750036 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1GRNSORT1 | |
| SCHEMBL5833197 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1GRNSORT1 | |
| SCHEMBL8254490 | 0.90 | MMEL1 (0.36) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL5869295 | 0.90 | MMEL1 (0.36) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL8248702 | 0.90 | MMEL1 (0.36) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL16290057 | 0.88 | CPB2 (0.33) | SMN1; SMN2CPB2CPB1 | |
| SCHEMBL13233704 | 0.88 | MAP3K7 (0.32) | — | |
| SCHEMBL8248643 | 0.87 | ACE2 (0.41) | GRNSORT1 | |
| SCHEMBL5870160 | 0.87 | ACE2 (0.41) | GRNSORT1 | |
| SCHEMBL30087493 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| US-20220054636-A1 | Chlorin Derivatives or Pharmaceutically Acceptable Salts Thereof, Preparation Method and Use Thereof, and Combination Thereof with an Ultrasonic Medical System | GUANGZHOU EEC BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-02-24 | — | — | US | disclosed |
| EP-3804725-A2 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | Rhode Island Hospital (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3220914-B1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
| EP-3148973-A1 | NOVEL COMPOUNDS OF THE 5-ACYLSULFANYL-HISTIDINE TYPE AS PRECURSORS OF THE CORRESPONDING 5-SULFANYLHISTIDINES AND THE DISULFIDES THEREOF | Tetrahedron (FR) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181507-A1 | NOVEL COMPOUNDS OF THE 5-ACYLSULFANYL-HISTIDINE TYPE AS PRECURSORS OF THE CORRESPONDING 5-SULFANYLHISTIDINES AND THE DISULFIDES THEREOF | TETRAHEDRON (FR) | 2015-12-03 | — | — | WO | disclosed |
| US-6989448-B2 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN | 2006-01-24 | — | — | US | disclosed |
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6469038-B1 | CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | CACNA1C, CACNA1I, CACNA1S | SMN1; SMN2 715/4885CPB2 1471/4885CPB1 882/4885 |
| US-20220054636-A1 | Chlorin Derivatives or Pharmaceutically Acceptable Salts Thereof, Preparation Method and Use Thereof, and Combination Thereof with an Ultrasonic Medical System | STAT6, JAK3, JAK1 | SMN1; SMN2 4140/4885CPB2 555/4885CPB1 627/4885 |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | SMN1; SMN2 292/4885CPB2 1711/4885CPB1 2181/4885 |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | SMN1; SMN2 292/4885CPB2 1711/4885CPB1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.